問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



MacKay Memorial Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 251New Taipei CityDanshuei

Recruiting Trial

41Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

291Cases

2017-07-01 - 2022-12-20

Phase III

Completed
An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

  • Condition/Disease

    Treatment-resistant Depression

  • Test Drug

    ESKETAMINE

Participate Sites
7Sites

Recruiting4Sites

Terminated3Sites

劉嘉逸
Linkou Chang Gung Medical Foundation

Division of Psychiatry

李信謙
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Psychiatry

2018-10-30 - 2022-12-31

Phase III

Completed
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    Erdafitinib

Participate Sites
12Sites

Recruiting2Sites

Terminated10Sites

吳文正
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2018-03-01 - 2021-03-31

Phase III

Completed
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Paliperidone Palmitate

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

楊延光
National Taiwan University Hospital

Division of Psychiatry

白雅美
Taipei Veterans General Hospital

Division of Psychiatry

2024-03-01 - 2027-12-31

Phase III

Active
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function

  • Condition/Disease

    Heart Failure

  • Test Drug

    capsule

Participate Sites
21Sites

Not yet recruiting11Sites

Recruiting10Sites

2023-07-01 - 2030-02-28

Phase III

Active
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)

  • Condition/Disease

    Locally Advanced Cervical Cancer

  • Test Drug

    Volrustomig

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2017-11-01 - 2027-12-31

Phase III

Active
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    Durvalumab/ Tremelimumab

Participate Sites
10Sites

Recruiting1Sites

Terminated9Sites

陳三奇
Taipei Veterans General Hospital

Division of Hematology & Oncology

2014-05-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2009-05-01 - 2010-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-12-29 - 2023-09-28

Phase III

Completed
A Phase III Trial of Chidamide in Combination with Exemestane in Patients with Hormone Receptor-Positive Advanced Breast Cancer (ACE)

  • Condition/Disease

    Hormone Receptor-Positive Advanced Breast Cancer

  • Test Drug

    NA

Participate Sites
9Sites

Recruiting6Sites

Terminated2Sites

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

劉良智
China Medical University Hospital-Taipei

未分科

2018-04-20 - 2023-02-28

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2 3 4 5 30
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB